A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Sponsor: Flare Therapeutics Inc.
Listed as NCT05929235, this PHASE1 trial focuses on Advanced Urothelial Carcinoma and Open Label and remains actively recruiting participants. Sponsored by Flare Therapeutics Inc., it has been updated 11 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jul 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Flare Therapeutics Inc.
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .